Lantheus Holdings, Inc. (NASDAQ:LNTH) Shares Purchased by Pier Capital LLC

Pier Capital LLC raised its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 43.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 87,497 shares of the medical equipment provider’s stock after buying an additional 26,479 shares during the period. Pier Capital LLC’s holdings in Lantheus were worth $7,827,000 at the end of the most recent quarter.

Other large investors also recently modified their holdings of the company. EntryPoint Capital LLC purchased a new position in Lantheus in the fourth quarter valued at about $210,000. Emerald Advisers LLC raised its position in shares of Lantheus by 4.4% in the 4th quarter. Emerald Advisers LLC now owns 3,976 shares of the medical equipment provider’s stock valued at $356,000 after purchasing an additional 169 shares in the last quarter. Harbor Advisors LLC acquired a new stake in shares of Lantheus during the fourth quarter worth approximately $224,000. KLP Kapitalforvaltning AS bought a new stake in shares of Lantheus in the fourth quarter worth $1,505,000. Finally, 1620 Investment Advisors Inc. acquired a new stake in Lantheus in the fourth quarter valued at $125,000. 99.06% of the stock is currently owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several brokerages have weighed in on LNTH. B. Riley decreased their price objective on shares of Lantheus from $127.00 to $122.00 and set a “buy” rating for the company in a report on Friday. Truist Financial boosted their price objective on Lantheus from $120.00 to $127.00 and gave the company a “buy” rating in a report on Thursday, February 27th. JMP Securities reaffirmed a “market outperform” rating and set a $112.00 target price on shares of Lantheus in a report on Tuesday, January 14th. Finally, The Goldman Sachs Group assumed coverage on Lantheus in a report on Wednesday, December 18th. They issued a “buy” rating and a $143.00 price target for the company. One equities research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus target price of $129.43.

Insider Transactions at Lantheus

In other Lantheus news, Director James H. Thrall sold 1,000 shares of Lantheus stock in a transaction on Wednesday, January 15th. The stock was sold at an average price of $94.76, for a total transaction of $94,760.00. Following the sale, the director now owns 33,207 shares of the company’s stock, valued at $3,146,695.32. The trade was a 2.92 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Robert J. Jr. Marshall sold 10,000 shares of the stock in a transaction on Monday, March 17th. The stock was sold at an average price of $100.52, for a total value of $1,005,200.00. Following the completion of the transaction, the chief financial officer now directly owns 113,860 shares of the company’s stock, valued at approximately $11,445,207.20. The trade was a 8.07 % decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders sold 64,109 shares of company stock worth $6,110,806. Insiders own 1.50% of the company’s stock.

Lantheus Stock Up 1.8 %

Shares of LNTH stock opened at $99.44 on Tuesday. The business has a 50 day moving average of $92.77 and a two-hundred day moving average of $96.47. The company has a market cap of $6.81 billion, a P/E ratio of 16.55 and a beta of 0.38. Lantheus Holdings, Inc. has a 52 week low of $57.92 and a 52 week high of $126.89.

Lantheus (NASDAQ:LNTH) last released its quarterly earnings data on Thursday, February 27th. The medical equipment provider reported $1.34 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.57 by ($0.23). Lantheus had a net margin of 28.57% and a return on equity of 44.29%. The company had revenue of $391.11 million for the quarter, compared to analyst estimates of $376.61 million. Analysts expect that Lantheus Holdings, Inc. will post 6.01 EPS for the current fiscal year.

About Lantheus

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.